Gail S. Page Appointed As Executive Chairperson Of NX Prenatal Inc.

May 27, 2015, 08:00 ET from NX Prenatal Inc.

LOUISVILLE, Ky., May 27, 2015 /PRNewswire/ -- NX Prenatal Inc., a privately held women's healthcare molecular diagnostic company, announced today that Gail S. Page has joined the Board of Directors and will serve as Executive Chairperson.  Ms. Page will be working with NX Prenatal to guide the commercial development of blood-based tests to support improved pregnancy outcomes.

"NX Prenatal has shown that its non-invasive technology can be used to identify biomarkers early in pregnancy that correlate with known adverse outcomes, such as spontaneous preterm birth," noted Ms. Page.  "This is a well-defined unmet medical need and developing blood based tests in this area will bring a much needed solution to physicians and patients alike.  I look forward to working with the NX Prenatal team to develop a comprehensive strategy that addresses this market opportunity which is clearly aligned with the current vision of physicians and payers to address early detection as opposed to treating costly outcomes downstream."

"We are very excited to have Gail's depth and breadth of experience in the diagnostics field," said Brian D. Brohman, NX Prenatal's Chief Executive Officer.  "Gail has been involved in the commercialization of a number of women's health diagnostic tests and will add great insight, passion and experience to our team, as we seek to launch breakthrough products than can significantly impact the health of mothers and their newborns, and help manage one of the industry's most costly outcomes in preterm birth."

Ms. Page served as the President, CEO and Director of Vermillion, Inc. from 2006 through 2012. Under her leadership, Vermillion successfully raised over $100M in funding, as it developed and commercially launched the first proteomic IVDMIA FDA cleared blood test to help diagnose ovarian cancer. Prior to Vermillion, Ms. Page served on the executive management teams of Laboratory Corporation of America and Luminex.

Ms. Page also founded Vineyard Investment Advisors in 2013 and currently works with entrepreneurs, businesses, and universities to transform their ideas into products and services.  She is a member of the American Association of Clinical Chemistry, the Greater Austin Chamber, and the National Association of Corporate Directors. Her current board appointments include Sword Diagnostics, Inc, Stellarray, Inc and Consortia Health, where she is the Cofounder and Executive Director. She is actively involved in the local/state community where she serves as a member of the Advisory Board for The Center for Professional Development and Entrepreneurship at MD Anderson, BBVA Compass Bank, and the National Association of Corporate Directors. In 2010, Ms. Page was recognized by Forbes Woman and Business Week for her work in the healthcare sector. In 2012, Ms. Page was a finalist for the Ernst and Young Entrepreneur of the Year in central Texas and was recognized as one of the top 20 business leaders in the Austin area. In 2014, Ms. Page was named by the Austin Business Journal as a "Woman of Influence and Power" in Central Texas. Most recently, Ms. Page was named a "Texas Xconomist" where she will be working with Xconomist throughout the US with an emphasis on the new ecosystem surrounding the Dell medical school.

About NX Prenatal

NX Prenatal Inc. is a private US based molecular diagnostics company located in Louisville, KY.  NX Prenatal is developing diagnostic assays for adverse pregnancy outcomes and conditions such as preterm birth.  NX Prenatal's proprietary NeXosome® platform enables the rapid isolation and enrichment of exosome and microvesicle particles from maternal blood.  These particles have been shown to be shed from the maternal and fetal tissues to help maintain a balance in certain immunologic and inflammatory processes that are common to successful pregnancy outcomes.  The biomarker content of these exosome particles can reflect early signs of dysfunction and dysregulation in those processes, which can lead to adverse outcomes. The company has unlocked a new library of biomarkers for prenatal risk assessment as early as 15 weeks gestation.  NX Prenatal is located in Louisville, KY.  For more information, please visit the company's website at

Logo -

SOURCE NX Prenatal Inc.